Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Swiss pharmaceutical giant Novartis has launched a not-for-profit medicines portfolio to help treat Covid-19 symptoms in patients in low-income and lower-middle-income countries.
As the disease currently lacks vaccine or curative treatment, the company aims to offer affordable drugs to address the major symptoms.
Covid-19 patients are known to experience inflammation and respiratory problems that can result in severe complications and even death.
The Covid-19 portfolio by Novartis includes 15 medicines from its Sandoz unit for treating gastro-intestinal illness, acute respiratory symptoms, pneumonia and septic shock.